Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow
Jyong Biotech schedules a bilingual Zoom-based virtual investor roadshow with StockFan, offering multiple time slots for global participants.
Rhea-AI Summary
Jyong Biotech (MENS) will participate in the StockFan Virtual Investor Non-Deal Roadshow on September 6–7, 2026, depending on time zone. The online event will be held via Zoom in both Mandarin Chinese and English to reach a global investor audience.
The session runs on Sunday, September 6, 2026, from 8:30–9:30 PM in New York (EDT) and 5:30–6:30 PM in Silicon Valley (PDT), and on Monday, September 7, 2026, from 8:30–9:30 AM in Taipei (CST). Interested investors, analysts, and media must register through a provided link to receive the Zoom ID and passcode. Jyong Biotech is a Taiwan-headquartered biotechnology company focused on plant-derived therapeutics for urinary system diseases, including its primary botanical drug candidate BOTRESO®.
Positive
- None.
Negative
- None.
Market Reaction – MENS
Following this news, MENS has gained 3.56%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $2.33.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 23 | Licensing strategy update | Positive | +2.6% | Company reaffirmed global licensing focus and highlighted the BPH market opportunity. |
| Jul 02 | Portfolio showcase | Positive | +8.3% | Company presented its botanical drug portfolio at the BIO 2026 convention. |
| May 29 | FDA pathway update | Positive | -2.2% | Management outlined additional studies and a potential NDA submission timeline. |
| May 15 | Annual report filing | Neutral | -3.4% | Company filed its Form 20-F annual report for fiscal year 2025. |
| Apr 28 | Market access update | Positive | +0.9% | Company updated market access strategies for its botanical drug candidates. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior news reactions were mostly positive, although the strategic interview and annual-report filing were followed by declines.
Key Terms
non-deal roadshow financial
botanical drug medical
preclinical-stage medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
New Taipei City, Taiwan/San Francisco, CA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced it will participate in StockFan Virtual Investor Non-Deal Roadshow on Sunday, September 6, 2026 (U.S. Eastern Time) / Monday, September 7, 2026 (Taipei Time).
Event Schedule
The virtual event will be conducted in both Mandarin Chinese and English, accessible across multiple time zones to accommodate the Company’s global investor base:
- New York (EDT): Sunday, September 6, 2026, from 8:30 PM to 9:30 PM
- Silicon Valley (PDT): Sunday, September 6, 2026, from 5:30 PM to 6:30 PM
- Taipei (CST): Monday, September 7, 2026, from 8:30 AM to 9:30 AM
Webcast registration
Investors, analysts, and media representatives are invited to join the meeting via Zoom. Please use the following link to register for the live event: https://luma.com/jfq4fafz. The Zoom ID and passcode will be sent after registration.
Participants are encouraged to log in to the meeting 5-10 minutes prior to the scheduled start time to ensure a timely connection.
About StockFan, Inc.
Based in Silicon Valley, California, StockFan is the ultimate stock market platform designed to connect, empower, and elevate the global investor community. By offering robust stock market data with a cutting-edge social ecosystem, StockFan unites fragmented financial market tools into a cohesive public market powerhouse. Its signature StockFan App has scaled to over 60 countries, serving a passionate user base of both retail and institutional investors. For more information, please visit http://stockfan.com.
About Jyong Biotech Ltd.
Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers' health needs and seeks to be a valuable business organization that is held in high esteem by the public. For more information, please visit: https://jyongir.com/.
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Jyong Biotech Ltd.
ir@jyongbio.com
Investor Relations
WFS Investor Relations Inc.
Email: services@wfsir.com
Phone: +1 628 283 9214
FAQ
When will Jyong Biotech (MENS) join the StockFan virtual investor non-deal roadshow?
Jyong Biotech will join the StockFan Virtual Investor Non-Deal Roadshow on Sunday, September 6, 2026, in New York and Silicon Valley, and on Monday, September 7, 2026, in Taipei. The event lasts one hour in each listed time zone.
What are the exact event times for the Jyong Biotech (MENS) StockFan virtual roadshow in different time zones?
The event runs on September 6, 2026, from 8:30 PM–9:30 PM EDT in New York and 5:30 PM–6:30 PM PDT in Silicon Valley, and on September 7, 2026, from 8:30 AM–9:30 AM CST in Taipei.
How can investors register for the Jyong Biotech (MENS) StockFan virtual investor event?
Investors, analysts, and media can register via the provided Zoom registration link at https://luma.com/jfq4fafz. After registration, participants receive the Zoom ID and passcode by email and are encouraged to log in 5–10 minutes before the start.
In which languages will the Jyong Biotech (MENS) StockFan virtual roadshow be conducted?
The Jyong Biotech StockFan virtual investor non-deal roadshow will be conducted in both Mandarin Chinese and English, aiming to serve the company’s global investor base across multiple regions and time zones.
What is Jyong Biotech (MENS) and what therapeutic area does it focus on?
Jyong Biotech is a Taiwan-headquartered, science-driven biotechnology company developing plant-derived (botanical) therapeutics. It mainly specializes in treatments for urinary system diseases and is advancing candidates such as its primary botanical drug BOTRESO® for markets in the U.S., EU, and Asia.
What is StockFan’s role in the Jyong Biotech (MENS) virtual non-deal roadshow?
StockFan is hosting the Virtual Investor Non-Deal Roadshow in which Jyong Biotech will participate. StockFan is described as a stock market platform that combines market data with a social ecosystem and serves users in over 60 countries through its StockFan App.